This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Data Demonstrating Potency Of Durata Therapeutics’ Dalbavancin Against Bacterial Pathogens Presented At ICAAC 2012

Durata Therapeutics (NASDAQ: DRTX) today announced data from an in vitro study and surveillance results of its lead product candidate, dalbavancin, currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The data, presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), demonstrate the potency of dalbavancin against numerous significant bacterial isolates in the United States and Europe.

Comparative In Vitro Activity of Dalbavancin (DAL) and Other Gram-Positive Agents Against a Recent Collection of European Bacterial Isolates (Simenauer, et al). Session Number 010, Presentation Number: C2-134

Study conclusions: On a MIC 90 (Minimum Inhibitory Concentration required to inhibit the growth of 90% of organisms) basis, dalbavancin was more potent than vancomycin, linezolid or daptomycin for every organism group studied. These findings indicate that dalbavancin continues to have potent activity against target pathogens isolated in Europe. (These in vitro data were generated by Dr. Dan Sahm and his team at Eurofins Medinet, Chantilly, Va.)

Update of Dalbavancin (DAL) Activity in the USA: Report from the SENTRY Program (2011). (Jones, et al). Session Number: 010, Presentation Number: C2-138

Study conclusions: Year 2011 SENTRY Program surveillance results for dalbavancin (DAL) document sustained potent activity against Staphylococcus aureus (SA), coagulase-negative staphylococci (CoNS), beta-hemolytic streptococci (βHS), viridans gr. streptococci (VGS) and vancomycin-susceptible (VANC-S) enterococci, that averaged four-to 32-fold greater than vancomycin, daptomycin or linezolid. Further development of dalbavancin appears warranted by these in vitro potency criteria. (These in vitro data were generated from the laboratories of Dr. Ron Jones and his coauthors at the Jones Microbiology Institute Laboratories in North Liberty, Iowa.)

“These results add to the growing body of evidence that dalbavancin is a highly potent agent against the Gram-positive bacteria associated with ABSSSI and many other infections of global concern,” said Durata Chief Medical Officer Michael Dunne, M.D. “We plan to use these data and clinical trial results to support our New Drug Application with the U.S. Food and Drug Administration for dalbavancin for the treatment of ABSSSI, which we continue to anticipate submitting in the first half of 2013.”

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,113.85 -18.01 -0.11%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,816.5120 -22.1310 -0.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs